The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000689370
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
18/05/2026
Date registered
Help: Date registered
10/06/2026
Date last updated
Help: Date last updated
9/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
10/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Identification of patients not responding to immune check point inhibitor therapy using CDI-DX001 PET
Scientific title
A Phase 1/2 open label, single arm study to evaluate the use of CDI-DX001 Positron Emission Tomography (CDI-DX001 PET) to identify patients with resectable, locally advanced or metastatic solid malignancy not responding to systemic immune checkpoint inhibitor treatment
Additional trial identifiers [1] 317267 0
CDI-DX001-IIT03
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Resectable solid malignancy 341891 0
Locally advanced solid malignancy 342081 0
Metastatic solid malignancy 342082 0
Condition category
Condition code
Cancer 337968 337968 0 0
Any cancer
Cancer 338191 338191 0 0
Lung - Non small cell
Cancer 338192 338192 0 0
Malignant melanoma
Cancer 338194 338194 0 0
Lung - Small cell
Cancer 338195 338195 0 0
Head and neck
Cancer 338196 338196 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 338197 338197 0 0
Cervical (cervix)
Cancer 338198 338198 0 0
Breast
Cancer 338199 338199 0 0
Oesophageal (gullet)
Cancer 338200 338200 0 0
Stomach

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
CDI-DX001 is an investigational radiopharmaceutical for imaging of multiple forms of cell death using PET/CT in near real time.

CDI-DX001 is administered as an intravenous (IV) bolus with the volume administered to study participants to be determined by the level of activity (MBq/mL) and the weight of the participant, with a target dose of 1.8 - 2.2MBq/kg (± 10%) (minimum 111MBq, maximum 259 MBq). CDI-DX001 will be administered by a qualified Nuclear Medicine Technician.

Study participants will undergo an approximately 30 minute PET/CT at 60 minutes ± 6 minutes post CDI-DX001 administration.

Each participant will undergo two (2) CDI-DX001 PET scans, one within 14 days prior to commencing treatment, and the second within 3-7 days (inclusive) after administration of cycle 2 of ICI of treatment. These two imaging visits will occur over an average period of approximately 8 weeks, and a maximum period of 15 weeks depending on treatment cycle length.

Participants will undertake standard of care treatment as per their treating oncologist. Participant outcomes will be collected from standard of care assessments for up to 12 months or until final closure of the study. This includes histological assessment of resected tissue (where available), standard imaging modalities (CT/MRI/FDG-PET) and/or biological markers where relevant.
Intervention code [1] 334062 0
Diagnosis / Prognosis
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345423 0
Sensitivity of CDI-DX001 tumour uptake measurements to correctly identify participants classified as non-responders by traditional methods.
Timepoint [1] 345423 0
12 weeks and 24 weeks after commencement of SoC treatment.
Secondary outcome [1] 461566 0
Safety of CDI-DX001.
Timepoint [1] 461566 0
After informed consent has been signed, until 7 (±1) days after the last dose of CDI-DX001.
Secondary outcome [2] 461568 0
Specificity of CDI-DX001 tumour uptake measurements to correctly identify participants classified as responders by traditional methods.
Timepoint [2] 461568 0
12 weeks, 24 weeks, and 12 months after commencement of SoC treatment.
Secondary outcome [3] 461569 0
Clinical utility of CDI-DX001 uptake measured by its impact on clinician decision-making.
Timepoint [3] 461569 0
At baseline (within 14 days prior to commencing SoC treatment) and at 24 weeks post initiation of SoC treatment.
Secondary outcome [4] 461570 0
Eligibility for CDI-DX001 companion theranostic treatment as determined by tumour uptake of CDI-DX001 among all participants.
Timepoint [4] 461570 0
At baseline (within 14 days prior to commencing SoC treatment) and within 3-7 days (inclusive) after administration of cycle 2 of ICI of treatment.
Secondary outcome [5] 462187 0
Tolerability of CDI-DX001
Timepoint [5] 462187 0
After informed consent has been signed, until 7 (±1) days after the last dose of CDI-DX001.

Eligibility
Key inclusion criteria
1. Signed informed consent will be obtained before any study specific procedure. Participants must be able to understand and willing to sign the written informed consent.
2. Male or female participants greater than or equal to 18 years of age.
3. Histologically or cytologically confirmed solid malignancy intended for immune checkpoint inhibitor treatment either alone or in combination with chemotherapy and/or radiotherapy.
4. At least one measurable lesion greater than or equal to 2 cm in maximum transaxial dimension. Where external beam radiotherapy is also being administered at least one measurable lesion must be outside of the irradiated volume in the opinion of the treating radiation oncologist.
5. Adequate renal function (eGFR >30 ml/min/1.73m2)
6. Female participants of non-childbearing potential (i.e post-menopausal [absence of menstrual bleeding for 1 year prior to screening, without any other medical reason], or has undergone hysterectomy or bilateral oophorectomy).
OR Female participants of childbearing potential with a negative serum pregnancy test within 7 days prior to the first CDI-DX001 PET scan, and must agree to use a highly effective and approved contraceptive method until 24 hours after the last CDI-DX001 PET scan.
OR Male participants who are capable of fathering a child must agree to use a highly effective and approved contraceptive method prior to the first CDI-DX001 PET scan until 24 hours after the last CDI-DX001 PET scan.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Cancer treatment within the previous 4 weeks. External beam radiotherapy is permitted within the previous 4 weeks provided there is at least one measurable lesion outside of the irradiated volume in the opinion of the treating radiation oncologist.
2. Major surgery within 4 weeks to the site / all sites of measurable disease. Biopsy is permitted. Where there is at least one site of measurable disease outside of the operative field, surgery within 4 weeks is permitted.
3. For solid malignancy of the urinary tract the disease must not be isolated to the kidney, ureter or bladder.
4. Active uncontrolled infection.
5. Congestive heart failure or prior NYHA class III-IV cardiac disease.
6. Uncontrolled hypertension (systolic BP > 180mmHg or diastolic BP >100mmHg).
7. Pregnancy.
8. Breast feeding.
9. Allergy to CDI-DX001 or any of its components.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 1 / Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 321841 0
Government body
Name [1] 321841 0
Cancer Institute NSW
Country [1] 321841 0
Australia
Primary sponsor type
Other Collaborative groups
Name
Centenary Institute of Cancer Medicine and Cell Biology
Address
Country
Australia
Secondary sponsor category [1] 324728 0
None
Name [1] 324728 0
Address [1] 324728 0
Country [1] 324728 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320382 0
Bellberry Human Research Ethics Committee F
Ethics committee address [1] 320382 0
Ethics committee country [1] 320382 0
Australia
Date submitted for ethics approval [1] 320382 0
24/03/2026
Approval date [1] 320382 0
24/04/2026
Ethics approval number [1] 320382 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150298 0
Dr Benjamin Kong
Address 150298 0
Dept Medical Oncology, Prince of Wales Hospital, 64-66 High St, Randwick, NSW 2031
Country 150298 0
Australia
Phone 150298 0
+61 2 9382 5111
Fax 150298 0
Email 150298 0
Contact person for public queries
Name 150299 0
Robert Daniels
Address 150299 0
Amplificare Pty Ltd, Suite 2.05, 1 York Street Sydney, NSW 2000 Australia
Country 150299 0
Australia
Phone 150299 0
+61 424 439 481
Fax 150299 0
Email 150299 0
Contact person for scientific queries
Name 150300 0
A/Prof Ivan Ho Shon
Address 150300 0
Amplificare Pty Ltd, Suite 2.05, 1 York Street Sydney, NSW 2000 Australia
Country 150300 0
Australia
Phone 150300 0
+61 2 9382 2200
Fax 150300 0
Email 150300 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.